Comparative safety study of two commercialised vaccines against canine babesiosis induced by babesia canis

Abstract

The safety of two vaccines available on the French market against canine babesiosis - Nobivac Piro® (NP) and Pirodog® (P) - have been evaluated. Their local, general and biochemical impacts have been compared in a controlled experimental study. Three groups were used: a control group (T) and two groups vaccinated twice at 21 days interval. All dogs presented moderate local reaction. However, either clinical and biological parameters showed that the NP group presented a significantly more intense reaction at the injection site compared to the P group. No statistical difference has been revealed between the groups P and T evolutions.